Session » (0067–0097) Rheumatoid Arthritis – Etiology and Pathogenesis Poster

Date: Sunday, October 26, 2025

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2025

10:30AM-12:30PM: Abstract Number: 0097

Aberrant histone marks increase the inflammatory phenotype of rheumatoid arthritis fibroblast-like synoviocytes (RA FLS) by suppressing NUB1 induction

10:30AM-12:30PM: Abstract Number: 0086

Androgen Upregulates Interferon Signaling in Osteoclast Differentiation During Inflammatory State

10:30AM-12:30PM: Abstract Number: 0076

Antibodies to malondialdehyde-acetaldehyde are associated with circulating inflammatory mediators during the preclinical stages of rheumatoid arthritis

10:30AM-12:30PM: Abstract Number: 0079

Association of Protein Arginine Deiminase 4 with the Myosin-9 Motor Complex

10:30AM-12:30PM: Abstract Number: 0078

Citrullinated Serum Albumin Is Not an Autoantigen in Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 0091

Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Rheumatoid Arthritis: associations with treatment response and comorbidities

10:30AM-12:30PM: Abstract Number: 0083

Confirmatory Factor Analysis of the Plutchik Suicide Risk Scale in Patients with Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 0094

Distinct immune-molecular signatures modulated ex vivo by JAK and TNF predict Rheumatoid Arthritis therapy outcomes in patients naïve to biologic and targeted synthetic DMARDs

10:30AM-12:30PM: Abstract Number: 0095

Effect of JAK Inhibitors on Osteoblast Differentiation

10:30AM-12:30PM: Abstract Number: 0089

Expansion of PD-1hi Tfh and Tph cells in the peripheral blood of seropositive clinically suspect arthralgia patients: association with progression to rheumatoid arthritis

10:30AM-12:30PM: Abstract Number: 0096

GLUT1-Dependent Targeting and Enhanced Selectivity of a Glucose-Methotrexate Conjugate in Rheumatoid Arthritis Fibroblast-Like Synoviocytes

10:30AM-12:30PM: Abstract Number: 0073

HLA-DQA1*01:02 Is Associated With IgG Multi-Reactivity With Citrulline-Containing Type II Collagen Epitopes While HLA-DRB*04:01 Is Associated With More Private Reactivity With Citrulline-Containing IgG Epitopes In Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 0082

IBI3011, a Humanized anti-IL1RAP Monoclonal Antibody, Inhibits IL1, IL33, IL36-driven Inflammation Pathway, and Attenuates Inflammation in Preclinical Inflammatory Disease Model

10:30AM-12:30PM: Abstract Number: 0067

Identification of Neutrophil Extracellular Traps in Explanted Human Lungs with Rheumatoid Arthritis-related Interstitial Lung Disease

10:30AM-12:30PM: Abstract Number: 0088

Imbalance of Inflammation-Regulating Microorganisms and Predicted Metabolomic Pathways Associates With Disease Evolution in Individuals At-Risk for Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 0072

Impact of Baricitinib on Cardiovascular Health in Biologic-naïve Rheumatoid Arthritis patients: A Comparative Study with TNF Inhibitors and Conventional DMARDs

10:30AM-12:30PM: Abstract Number: 0075

Impact of CXCL2 and IL-11 from Rheumatoid Arthritis Synovial Fibroblasts on Angiogenesis and Endothelial Cell Network Formation

10:30AM-12:30PM: Abstract Number: 0070

Integrating Synovial Protein Signatures and Serum Profiles to Predict Disease Activity and Treatment Response in Early Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 0087

Integrative Metabolomic and Inflammatory Profiling in Rheumatoid Arthritis: Disease activity, therapeutic modulation, and underlying hepatic mechanisms

10:30AM-12:30PM: Abstract Number: 0090

Interleukin-36β modulates the progression of rheumatoid arthritis by altering the behavior of rheumatoid arthritis synovial fibroblasts

10:30AM-12:30PM: Abstract Number: 0084

Regulation of the same chemokine gene transcription by different histone lysine methyltransferases, MLL1 and MLL3, in rheumatoid arthritis synovial fibroblasts

10:30AM-12:30PM: Abstract Number: 0074

Rheumatoid Factors (RFs) in RA Patient Sera Do Not Bind To Fc-Free Certolizumab Pegol, But Do Bind To Fc-Containing Anti-TNF-α Biological DMARDs, Driving Immune Complex Formation and Cellular Clearance

10:30AM-12:30PM: Abstract Number: 0085

Single Cell RNA-seq Revealed Immune/epithelial Cell Abnormalities Underlying the Pathogenesis of Rheumatoid Arthritis-related Interstitial Lung Disease

10:30AM-12:30PM: Abstract Number: 0093

Soluble CD13 engages protease-activated receptor 4 to promote synovial inflammation and angiogenesis in rheumatoid arthritis

10:30AM-12:30PM: Abstract Number: 0069

Spatial transcriptomics in rheumatoid arthritis (RA) synovium reveals distinct region-specific fibroblast functions

10:30AM-12:30PM: Abstract Number: 0092

SynovAI: A Revolutionary AI Framework for Enhanced Detection and Differentiation of Rheumatoid Arthritis, Osteoarthritis, and Spondyloarthritis via Advanced Ultrasound Imaging

10:30AM-12:30PM: Abstract Number: 0080

The Role of DICAM in Modulating Macrophage Differentiation and Inflammatory Responses via αvβ3 Integrin Signaling in Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 0081

Trans-endothelial Trafficking of Fibroblast-like Synoviocytes Amplifies Synovial Inflammation in Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 0077

Transformer-based multi-omics study identifies important role of glycine, serine and threonine metabolism pathway in rheumatoid arthritis complicated by anemia

10:30AM-12:30PM: Abstract Number: 0068

Unique Fibroblast-like Synoviocyte Phenotype with Elevated MCSF Expression Induced by TLR5 Activation in Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 0071

Unravelling Transcriptomic Landscapes in Rheumatoid Arthritis and Systemic Lupus Erythematosus: Shared and Unique Molecular Signatures related to relevant clinical features.

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].